Exenatide + Insulin
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stress Hyperglycemia
Conditions
Stress Hyperglycemia
Trial Timeline
Jan 1, 2015 → Dec 1, 2016
NCT ID
NCT01969149About Exenatide + Insulin
Exenatide + Insulin is a phase 2/3 stage product being developed by Eli Lilly for Stress Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01969149. Target conditions include Stress Hyperglycemia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02432976 | Phase 2/3 | Completed |
| NCT01969149 | Phase 2/3 | Completed |
| NCT00099333 | Phase 2 | Completed |
Competing Products
20 competing products in Stress Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + placebo | Eli Lilly | Phase 2 | 52 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Thermal stress and performance without a pre-cooling protocol | Petros Pharmaceuticals | Pre-clinical | 15 |
| solifenacin | Astellas Pharma | Approved | 85 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| duloxetine + Placebo | Eli Lilly | Phase 2 | 52 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| duloxetine HCl | Eli Lilly | Approved | 85 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine hydrochloride + placebo | Eli Lilly | Approved | 85 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine Hydrochloride + placebo | Eli Lilly | Phase 3 | 77 |